Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Higgins

Showing results (231-240 of 283) with videos related to

Pageof 29
Sort By:
Advances in Bioscience and Biotechnology (Print)|January 29, 2013
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblastsThomas H Sisson, Toby M Maher, Iyabode O Ajayi, et al.
Journal of Patient-Reported Outcomes|May 18, 2018
Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diaryPeter D R Higgins, Gale Harding, Nancy K Leidy, et al.
Inflammatory Bowel Diseases|January 25, 2024
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT TrialsGeert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, et al.
Digestive Diseases and Sciences|October 27, 2023
Correction to: Efficacy and Safety of Dual Targeted Therapy for Partially or Non‑responsive Inflammatory Bowel Disease: A Systematic Review of the LiteratureElliot M Berinstein, Jessica L Sheehan, Janson Jacob, et al.
Clinical and Translational Gastroenterology|March 7, 2023
Self-Efficacy and the Impact of Inflammatory Bowel Disease on Patients' Daily LivesJessica L Sheehan, LaVana Greene-Higgs, Linnea Swanson, et al.
Digestive Diseases and Sciences|April 1, 2026
The Multiple Dimensions of Self-Management in Active Inflammatory Bowel Disease: A Qualitative Analysis of Patients' Daily Lived ExperiencesShirley Cohen-Mekelburg, Gal Hodish, Drew Ebner, et al.
Crohn'S & Colitis 360|September 9, 2022
Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter RegistryEdward L Barnes, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Inflammatory Bowel Diseases|April 24, 2026
Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitisManjeet K Goyal, Priyata Dutta, Matthew C Choy, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2025
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension studyRemo Panaccione, Séverine Vermeire, Silvio Danese, et al.
Digestive Diseases and Sciences|June 24, 2026
Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-MakingReid Herran, Samuel Wilcox, Gal Hodish, et al.
Pageof 29

Showing results (231-240 of 283) with videos related to

Sort By:
Pageof 29
Advances in Bioscience and Biotechnology (Print)|January 29, 2013
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblastsThomas H Sisson, Toby M Maher, Iyabode O Ajayi, et al.
Journal of Patient-Reported Outcomes|May 18, 2018
Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diaryPeter D R Higgins, Gale Harding, Nancy K Leidy, et al.
Inflammatory Bowel Diseases|January 25, 2024
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT TrialsGeert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, et al.
Digestive Diseases and Sciences|October 27, 2023
Correction to: Efficacy and Safety of Dual Targeted Therapy for Partially or Non‑responsive Inflammatory Bowel Disease: A Systematic Review of the LiteratureElliot M Berinstein, Jessica L Sheehan, Janson Jacob, et al.
Clinical and Translational Gastroenterology|March 7, 2023
Self-Efficacy and the Impact of Inflammatory Bowel Disease on Patients' Daily LivesJessica L Sheehan, LaVana Greene-Higgs, Linnea Swanson, et al.
Digestive Diseases and Sciences|April 1, 2026
The Multiple Dimensions of Self-Management in Active Inflammatory Bowel Disease: A Qualitative Analysis of Patients' Daily Lived ExperiencesShirley Cohen-Mekelburg, Gal Hodish, Drew Ebner, et al.
Crohn'S & Colitis 360|September 9, 2022
Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter RegistryEdward L Barnes, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Inflammatory Bowel Diseases|April 24, 2026
Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitisManjeet K Goyal, Priyata Dutta, Matthew C Choy, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2025
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension studyRemo Panaccione, Séverine Vermeire, Silvio Danese, et al.
Digestive Diseases and Sciences|June 24, 2026
Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-MakingReid Herran, Samuel Wilcox, Gal Hodish, et al.
Pageof 29